SETDB2 and type 2 diabetes mellitus: The MoMs treated with sera from T2D patients demonstrated decreased SETDB2 expression compared to treatment with serum from nondiabetic patients with COVID-19 (Fig. 5A and SI Appendix, Fig. S8).